Transpapillary drainage has no added benefit on treatment outcomes in patients undergoing EUS-guided transmural drainage of pancreatic pseudocysts: A large multicenter study

Dennis Yang, Sunil Amin, Susana Gonzalez, Daniel Mullady, Stephen Hasak, Srinivas Gaddam, Steven A. Edmundowicz, Mark A. Gromski, John M. Dewitt, Mohamad El Zein, Mouen A. Khashab, Andrew Y. Wang, Jonathan P. Gaspar, Dushant S. Uppal, Satish Nagula, Samir Kapadia, Jonathan M. Buscaglia, Juan Carlos Bucobo, Alex Schlachterman, Mihir S. WaghPeter V. Draganov, Min Kyu Jung, Tyler Stevens, John J. Vargo, Harshit S. Khara, Mustafa Huseini, David L. Diehl, Rajesh N. Keswani, Ryan Law, Srinadh Komanduri, Patrick S. Yachimski, Tomas Davee, Anoop Prabhu, Robert T. Lapp, Richard S. Kwon, Rabindra R. Watson, Adam J. Goodman, Natasha Chhabra, Wallace J. Wang, Petros Benias, David L. Carr-Locke, Christopher J. Dimaio*

*Corresponding author for this work

Research output: Contribution to journalArticle

42 Scopus citations

Abstract

Background and Aims The need for transpapillary drainage (TPD) in patients undergoing transmural drainage (TMD) of pancreatic fluid collections (PFCs) remains unclear. The aims of this study were to compare treatment outcomes between patients with pancreatic pseudocysts undergoing TMD versus combined (TMD and TPD) drainage (CD) and to identify predictors of symptomatic and radiologic resolution. Methods This is a retrospective review of 375 consecutive patients with PFCs who underwent EUS-guided TMD from 2008 to 2014 at 15 academic centers in the United States. Main outcome measures included TMD and CD technical success, treatment outcomes (symptomatic and radiologic resolution) at follow-up, and predictors of treatment outcomes on logistic regression. Results A total of 375 patients underwent EUS-guided TMD of PFCs, of which 174 were pseudocysts. TMD alone was performed in 95 (55%) and CD in 79 (45%) pseudocysts. Technical success was as follows: TMD, 92 (97%) versus CD, 35 (44%) (P =.0001). There was no difference in adverse events between the TMD (15%) and CD (14%) cohorts (P =.23). Median long-term (LT) follow-up after transmural stent removal was 324 days (interquartile range, 72-493 days) for TMD and 201 days (interquartile range, 150-493 days) (P =.37). There was no difference in LT symptomatic resolution (TMD, 69% vs CD, 62%; P =.61) or LT radiologic resolution (TMD, 71% vs CD, 67%; P =.79). TPD attempt was negatively associated with LT radiologic resolution of pseudocyst (odds ratio, 0.11; 95% confidence interval, 0.02-0.8; P =.03). Conclusions TPD has no benefit on treatment outcomes in patients undergoing EUS-guided TMD of pancreatic pseudocysts and negatively affects LT resolution of PFCs.

Original languageEnglish (US)
Pages (from-to)720-729
Number of pages10
JournalGastrointestinal endoscopy
Volume83
Issue number4
DOIs
StatePublished - Apr 1 2016

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Gastroenterology

Fingerprint Dive into the research topics of 'Transpapillary drainage has no added benefit on treatment outcomes in patients undergoing EUS-guided transmural drainage of pancreatic pseudocysts: A large multicenter study'. Together they form a unique fingerprint.

  • Cite this

    Yang, D., Amin, S., Gonzalez, S., Mullady, D., Hasak, S., Gaddam, S., Edmundowicz, S. A., Gromski, M. A., Dewitt, J. M., El Zein, M., Khashab, M. A., Wang, A. Y., Gaspar, J. P., Uppal, D. S., Nagula, S., Kapadia, S., Buscaglia, J. M., Bucobo, J. C., Schlachterman, A., ... Dimaio, C. J. (2016). Transpapillary drainage has no added benefit on treatment outcomes in patients undergoing EUS-guided transmural drainage of pancreatic pseudocysts: A large multicenter study. Gastrointestinal endoscopy, 83(4), 720-729. https://doi.org/10.1016/j.gie.2015.10.040